Dr. Reddy's Laboratories Limited (NSE:DRREDDY)
India · Delayed Price · Currency is INR | Market Cap | 1.07T |
| Revenue (ttm) | 334.26B |
| Net Income (ttm) | 56.80B |
| Shares Out | n/a |
| EPS (ttm) | 68.11 |
| PE Ratio | 18.85 |
| Forward PE | 20.65 |
| Dividend | 8.00 (0.62%) |
| Ex-Dividend Date | Jul 10, 2025 |
| Volume | 1,553,743 |
| Average Volume | 1,414,608 |
| Open | 1,280.00 |
| Previous Close | 1,277.90 |
| Day's Range | 1,271.60 - 1,290.00 |
| 52-Week Range | 1,020.00 - 1,421.50 |
| Beta | 0.38 |
| RSI | 54.25 |
| Earnings Date | Jul 23, 2025 |
About Dr. Reddy's Laboratories
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company North America, Europe, India, Russia, and internationally. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segment. The Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages i... [Read more]
Financial Performance
In 2024, Dr. Reddy's Laboratories's revenue was 325.54 billion, an increase of 16.61% compared to the previous year's 279.16 billion. Earnings were 56.54 billion, an increase of 1.54%.
Financial StatementsNews
This Indian pharma company sees a big opportunity in generic versions of weight-loss drugs
Dr. Reddy's Laboratories is betting big on a new wave of growth fueled by a global demand for weight-loss drugs.
Big Indian pharma is coming for Ozempic and Wegovy
Dr. Reddy's CEO Erez Israeli talks about the Indian pharma's plans to introduce a low-cost generic version of semaglutide - the active ingredient used in blockbuster weight-loss drugs Wegovy and Ozemp...
Dr. Reddy’s shares jump over 3% following Q1 results – Should you buy, hold or sell? Know More
Shares of Dr. Reddy’s Laboratories surged 3.06% to Rs 1,285.60 on Wednesday after the company reported its Q1 FY26 financial results. The stock touched an intraday high of Rs 1,287.90 and now commands...
Dr Reddy’s stock: CLSA, Jefferies recommend sell, Morgan Stanley says hold — here’s why
Top brokerages have delivered a mixed outlook on Dr. Reddy’s Laboratories following its Q1FY26 results. While Jefferies and CLSA retained their Underperform ratings citing concerns over U.S. business ...
Dr Reddy’s share: Morgan Stanley maintains equal-weight, sets Rs 1,298 target after Q1 margin pressure
Morgan Stanley has maintained its Equal-Weight rating on Dr. Reddy’s Laboratories, assigning a target price of ₹1,298 per share. The target indicates a modest upside from the current market price of ₹...
Dr Reddy’s share: Jefferies sees 12% downside after Q1 miss, cuts target to Rs 1,100
Jefferies has maintained its Underperform rating on Dr. Reddy’s Laboratories, lowering expectations with a target price of ₹1,100 per share. This implies a 12% downside from the current market price o...
Dr Reddy’s share: CLSA sees 10% downside, flags tapering US momentum and gRevlimid slowdown
CLSA has maintained its Underperform rating on Dr. Reddy’s Laboratories, assigning a target price of ₹1,120 per share, implying a 10% downside from the current market price of ₹1,248.00. The brokerage...
Dr. Reddy's Laboratories Limited (RDY) Q1 2026 Earnings Call Transcript
Dr. Reddy's Laboratories Limited 2026 Q1 - Results - Earnings Call Presentation
Dr Reddy’s PAT rises 2% despite record quarterly revenues in Q1FY26
Hyderabad: Despite clocking its highest-ever quarterly revenues during the first quarter ended June 30, pharma major Dr Reddy's Laboratories (DRL) on .
Dr. Reddy's Q1FY26 Financial Results
HYDERABAD, India--(BUSINESS WIRE)---- $RDY #ConsolidatedFinancialResults--Dr. Reddy's Laboratories Ltd. today announced its consolidated financial results for the quarter ended June 30, 2025.
Dr. Reddy’s to launch generic semaglutide in 87 countries: Bloomberg
India's Dr Reddy's to launch generic obesity drugs in 87 countries next year, CEO says
Dr Reddy's Laboratories plans to launch a cheaper copycat version of Novo Nordisk's blockbuster weight-loss drug Wegovy in 87 countries next year, the Indian drugmaker's CEO, Erez Israeli, said on Wed...
Dr. Reddy's GAAP EPS of $0.20, revenue of $997M misses by $3M
Dr Reddy’s Laboratories Q1 Results: Revenue jumps 11.4% YoY to Rs 8,545 crore, net profit marginally up
Dr. Reddy’s Laboratories kicked off the fiscal year on a solid note, posting its Q1 FY26 results with a healthy revenue increase but a slight dip in margins. The Hyderabad-based pharma giant reported ...
Q1FY26 results today: Infosys, Tata Consumer, Dr Reddy’s, SRF, Persistent among 40 companies to announce earnings on July 23
Investors will closely watch quarterly earnings from several key companies scheduled to report their Q1FY26 results today, July 23, 2025. Among the most anticipated are Infosys, Tata Consumer Products...
Q1 Results Today, 23rd July: Infosys, Dr Reddy’s, Tata Consumer, Coforge among top companies
India Inc.’s earnings season picks up pace today as several leading companies across sectors are set to announce their financial results for the quarter ended June 30, 2025 (Q1 FY26). After bellwether...
Dr. Reddy's Q1 Earnings Preview
Top stocks to watch today, July 22: Titan, UltraTech, Dr Reddy’s in focus; Havells, Bajaj Finance under pressure
A host of stocks are likely to remain in focus on Monday, July 22, driven by fresh corporate developments, Q1 earnings announcements, and new brokerage commentary. Here are the key names to track: Pos...
Why Is Alvotech Stock Trading Higher On Wednesday?
Alvotech (NASDAQ: ALVO) shares saw a positive lift Wednesday morning following the announcement that the biosimilar developer has significantly bolstered its production capabilities by acquiring Swis...
Nifty top losers today, July 8: Titan Company, Dr. Reddy’s Laboratories, Cipla, Bajaj Auto, Trent and more
Indian stock markets closed Monday, July 8, on a positive note, with both benchmark indices finishing in the green. The Sensex gained 270.01 points to settle at 83,712.51, while the Nifty 50 edged up ...
Nifty top gainers today, July 4: Bajaj Finance, Dr. Reddy’s, Infosys, Hindustan Unilever, ICICI Bank and more
Indian equity benchmarks ended the July 4 trading session on a positive note, despite intraday volatility. The BSE Sensex gained 193.42 points, or 0.23%, to close at 83,432.89. Meanwhile, the NSE Nift...
Nifty 50 top gainers today, July 3: Dr. Reddy’s, Apollo Hospitals, Hero MotoCorp, ONGC and more
Indian equity markets closed in the red on Wednesday, July 3, after a choppy trading session. The benchmark indices slipped slightly, with the Sensex falling 170 points to settle at 83,239.47, while t...
Nifty 50 top losers this week (June 28): ONGC, Dr. Reddy’s, Tech Mahindra, Maruti Suzuki India and more
Indian stock markets wrapped up the week on a strong note, with benchmark indices extending their gains for the second consecutive week. Both the Sensex and Nifty 50 advanced over 2%, supported by bro...
Nifty 50 top losers today, June 27: Tata Consumer Products, Dr. Reddy’s, Wipro, SBI Life and more
Indian stock markets ended on a high note on June 27, with the Sensex rising 303 points to 84,058.90 and the Nifty gaining 88.80 points to close at 25,637.80. However, not all stocks shared in the ral...